Affiliation:
1. Department of Pharmacy, Health Sciences Center, Federal University of Santa Maria, Santa Maria, Brazil
Abstract
Background:
Although evaluating in vitro biological activity is an important part of the drug
discovery process, few publications discuss the ideal inhibitory activity in these tests.
Objective:
To analyze the in vitro biological activity data from antiviral drugs to establish parameters that
could increase success in developing new antiviral drug candidates.
Methods:
Information from in vitro tests for each antiviral medicine was obtained from the Thomson
Reuters Integrity platform for antiviral drugs approved by FDA between 1963 and 2020 (35 years). The
inhibitory activity data was collected from three references using the same determination method, and the
values were reported as means.
Results:
82 antiviral drugs were found to treat 11 different viruses. Most of these drugs were developed to
treat HIV infections (33 of 82), followed by anti-HCV medicines (20 of 82). The anti-HIV phenotypic
activities of most HIV-approved drugs had an IC50 < 50 nM; for the anti-HCV it was verified as IC50 <
0.2 μM. Combining the data for all drugs analyzed, the antiviral phenotypic activity in most cases exhibited
an IC50 < 0.2 μM.
Conclusions:
The limited availability of antiviral drugs and in vitro activity data imposed limitations on
this study. However, it could be inferred that an antiviral drug candidate would have more success in drug
development when the IC50 was in the range of low micromolar. Ultimately, in vitro activity must be
considered in combination with other factors in drug development processes.
Funder
FAPERGS [Fundação de Amparo à Pesquisa do Estado do Rio Grande do Sul]
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献